Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

TSXV:HEM - Post Discussion

Hemostemix Inc > Results
View:
Post by ENEMENEMYNEMO on Aug 30, 2022 10:26am

Results

Critical Limb results are mediocre however the release of Cardic data is phenomenal!!!

The heart is where the money is at, now I can see (maybe Walt too) why TS kept pushing the comment on the CLI trial giving us safety data!  This can be used to a great deal to support safety in a PhaseII Cardiac Study. 14% improvement in dilated cardiomyopathy blows MyoKardia out of the sky.  Mind with that's a pill and this is an invasive cardiac procedure, but a one-off and we know how often Gramps forgets to take his meds. 

This is marketable for partnership / BO  


Im cashing in on the low today and loading up my position!

Comment by JocetooBad on Aug 30, 2022 10:39am
Yeah, mediocre on CLI, absolutely now I understand why TS was highlighting the Phase II trial was about demonstrating safety of the treatment. It does look safe, but the effectiveness is underwhelming at best. With a bigger sample we'd know better, but argh this is going to take long, and take a lot more $. I hope the cardio path takes us somewhere faster. GLTA
Comment by ENEMENEMYNEMO on Aug 30, 2022 12:17pm
Hopefullly something is in the works... I'd expect huge volume if this was felt by institutional to be terrible news 250k "sell off" is nothin
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities